The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans

British Journal of Clinical Pharmacology

Volumn 48, Issue 2, 1999, Pages 180-189

  Sandström, Rikard ^a   Knutson, Tina W ^b   Knutson, Lars ^b   Jansson, Britt ^a   Lennernäs, Hans ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Absorption; CYP3A metabolism; Intestinal permeability; Intestinal secretion; Ketoconazole; P glycoprotein; Verapamil

Indexed keywords

GLYCOPROTEIN P; KETOCONAZOLE; PHENAZONE; VERAPAMIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; FIRST PASS EFFECT; HUMAN; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; INTRAVENOUS DRUG ADMINISTRATION; JEJUNUM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ALGORITHMS; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; JEJUNUM; KETOCONAZOLE; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; PERFUSION; STEREOISOMERISM; VERAPAMIL;

EID: 0032786547     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00999.x     Document Type: Article

References (35)

1. 1 Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-497.
2. 2 Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24.
3. 3 Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C. Pharmacokinetics of felodipine in patients with liver disease. Eur J Clin Pharmacol 1989; 36: 473-479.
4. 4 Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24: 796-801.
5. 5 Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-1036.
6. 6 Lown KS, Ghosh M, Watkins PB. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab Dispos 1998; 26: 185-187.
7. 7 Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
8. 8 Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-1562.
9. 9 Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84: 265-269.
10. 10 Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450, 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy, Mol Carcinog 1995; 13: 129-134.
11. 11 Benet LZ, Wu CY, Hebert MF, Wacher VJ. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Controlled Release 1996; 39: 139-143.
12. 12 Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
13. 13 Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997; 94: 2031-2035.
14. 14 Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-260.
15. 15 Sandstrom R, Karlsson A, Knutson L, Lennernas H. Jejunal absorption and metabolism of R/S verapamil in humans [In Process Citation]. Pharm Res 1998; 15: 856-862.
16. 16 Ervine CM, Matthew DE, Brennan B, Houston JB. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Drug Metab Dispos 1996; 24: 211-215.
17. 17 Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 1994; 151: 485-491.
18. 18 Stein WD. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 1997; 77: 545-590.
19. 19 Fagerholm U, Johansson M, Lennernäs H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13: 1336-1342.
20. 20 Knutson L, Odlind B, Hallgren R. A new technique for segmental jejunal perfusion in man. Am J Gastroenterol 1989; 84: 1278-1284.
21. 21 Lennernas H, Ahrenstedt O, Hallgren R, Knutson L, Ryde M, Paalzow LK. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 1992; 9: 1243-1251.
22. 22 Sandström R, Lennernäs H, Öhlén K, Karlsson A-J. Enantiomeric separation of verapamil and norverapamil using chiral AGP as the stationary phase, Pharmacol Biomed Anal, in press.
23. 23 Lennernas H, Fagerholm U, Raab Y, Gerdin B, Hallgren R. Regional rectal perfusion: a new in vivo approach to study rectal drug absorption in man. Pharm Res 1995; 12: 426-432.
24. 24 Stagni G, Gillespie WR. Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 667: 349-354.
25. 25 Hedman A, Angelin B, Arvidsson A, et al. Digoxin verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991; 49: 256-262.
26. 26 Robinson MA, Mehvar R. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: The role of plasma protein binding. Biopharm Drug Dispos 1996; 17: 577-587.
27. 27 Kroemer HK, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data; contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992; 260: 1052-1057.
28. 28 Purves RD. A Macintosh application far non-linear parameter estimation. 1994, Pharmacology Department, University of Otago, Dunedin, New Zealand.
29. 29 Langenbucher F. Numerical convolution/deconvolution as a tool for correlation in vitro in vivo drug availability. Pharm Ind 1982; 44: 1166-1172.
30. 30 Lennernas H, Knutsson L, Hussain A, Lesko L, Salmonson T, Amidon GL. The human jejunal Peff-value for each enatiomer of (R,S) -verapamil. Pharm Res 1996; 13: 246.
31. 31 Lown KS, Kolars JC, Ghosh M, Schmiedlin-Ren P, Watkins PB. Induction of MDR 1 expression in normal rat and human intestine in vivo. Gastroenterology 1996; 110: A344.
32. 32 Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression [see comments]. J Clin Invest 1997; 99: 2545-2553.
33. 33 Lindahl A, Sandstrom R, Ungell AL, et al. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther 1996; 60: 493-503.
34. 34 Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-49.
35. 35 Kim RB, Wandel C, Leake B et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-14.